Table 3 Adjusted vaccine effectiveness against Covid-19 outcomes of at least two-dose, and three-dose of inactivated Covid-19 vaccines versus no vaccination
Subset 1: at least two-dose group VE (95% CI) | Subset 2: three-dose group VE (95% CI) | |||||
|---|---|---|---|---|---|---|
Documented SARS-CoV-2 Infection | Severe/critical Covid-19 | Covid-19 related death | Documented SARS-CoV-2 Infection | Severe/critical Covid-19 | Covid-19 related death | |
Overall | 25.9 (24.9, 26.9) | 87.5 (84.0, 90.2) | 94.0 (88.9, 96.7) | 47.6 (46.7, 48.6) | 94.9 (92.0, 96.7) | 99.2 (94.2, 99.9) |
Age group | ||||||
60–69 years old | 23.9 (22.6, 25.2) | 92.5 (87.9, 95.4) | 96.8 (87.0, 99.2) | 45.2 (44.0, 46.5) | 96.0 (91.0, 98.3) | 100 (NA) |
70–79 years old | 27.8 (25.8, 29.7) | 82.9 (75.3, 88.2) | 90.3 (77.6, 95.8) | 50.6 (48.8, 52.3) | 95.6 (90.0, 98.1) | 100 (NA) |
80–89 years old | 40.4 (36.3, 44.2) | 85.9 (76.9, 91.4) | 95.9 (83.1, 99.0) | 59.9 (56.1, 63.3) | 94.2 (85.7, 97.7) | 100 (NA) |
90 years old and above | 53.2 (37.8, 64.8) | 71.6 (13.9, 90.7) | 85.8 (−15.5, 98.3) | 69.0 (53.3, 79.5) | 66.8 (-22.5, 91.0) | 80.2 (−69.4, 97.7) |
Sex | ||||||
Male | 24.6 (23.1, 26.0) | 86.6 (79.2, 91.3) | 95.3 (84.9, 98.5) | 48.6 (47.2, 50.0) | 92.3 (84.1, 96.2) | 97.4 (81.3, 99.6) |
Female | 27.2 (25.7, 28.6) | 87.8 (83.6, 90.9) | 93.2 (86.2, 96.7) | 46.7 (45.3, 48.1) | 95.8 (92.5, 97.6) | 100 (NA) |
Chronic disease | ||||||
0 | 22.2 (20.8, 23.6) | 89.3 (84.2, 92.8) | 97.1 (90.9, 99.1) | 44.3 (42.9, 45.6) | 97.1 (92.9, 98.8) | 100 (NA) |
≥1 | 30.8 (29.3, 32.3) | 86.0 (80.8, 89.7) | 89.7 (78.6, 95.0) | 52.0 (50.6, 53.4) | 93.1 (88.3, 95.9) | 98.1 (86.5, 99.7) |
